A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus

PLoS Neglected Tropical Diseases

Volumn 10, Issue 1, 2016, Pages

  McCarthy, Stephen D S ^a   Majchrzak Kita, Beata ^b   Racine, Trina ^c   Kozlowski, Hannah N ^a   Baker, Darren P ^d   Hoenen, Thomas ^e   Kobinger, Gary P ^c   Fish, Eleanor N ^a,b   Branch, Donald R ^a,b,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d BIOGEN   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f CANADIAN BLOOD SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BRINCIDOFOVIR; CIDOFOVIR; CONSENSUS INTERFERON; FAVIPIRAVIR; LAMIVUDINE; MARAVIROC; NUCLEOSIDE ANALOG; TENOFOVIR; TENOFOVIR DISOPROXIL; TOREMIFENE; VIRUS RNA; ZIDOVUDINE; ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; NUCLEOSIDE; TRIAZOLE DERIVATIVE;

ARTICLE; CELL VIABILITY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; IC50; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SURVIVAL RATE; VIRUS REPLICATION; DRUG EFFECTS;

ANTIVIRAL AGENTS; CCR5 RECEPTOR ANTAGONISTS; CYCLOHEXANES; EBOLAVIRUS; HUMANS; INTERFERON-BETA; NUCLEOSIDES; TOREMIFENE; TRIAZOLES; VIRUS REPLICATION;

EID: 84969416041     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004364     Document Type: Article

References (34)

1. World Health Organization, Ebola Situation Report – 16 December 2015. http://apps.who.int/ebola/en/current-situation/ebola-situation-report-13-december-2015.
2. Wong G, Audet J, Fernando L, Fausther-Bovendo H, Alimonti JB, Kobinger GP, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 2014;32: 5722–9. doi: 10.1016/j.vaccine.2014.08.028 25173474
3. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20: 1126–9. doi: 10.1038/nm.3702 25194571
4. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514: 47–53. doi: 10.1038/nature13777 25171469
5. Wong KK, Perdue CL, Malia J, Kenney JL, Peng S, Gwathney JK, et al. Supportive Care of the First 2 Ebola Virus Disease Patients at the Monrovia Medical Unit. Clin Infect Dis. 2015;61:e47–51. doi: 10.1093/cid/civ420 26021993
6. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S, Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17–21. doi: 10.1016/j.antiviral.2014.02.014 24583123
7. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508: 402–5. doi: 10.1038/nature13027 24590073
8. Florescu DF, Keck MA, Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev Anti Infect Ther. 2014;12: 1171–8. doi: 10.1586/14787210.2014.948847 25120093
9. Muhlberger E, Weik M, Volchkov VE, Klenk HD, Becker S, Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol. 1999;73: 2333–42. 9971816
10. Jácome R, Becerra A, de León SP, Lazcano A, Structural Analysis of Monomeric RNA- Dependent Polymerases: Evolutionary and Therapeutic Implications. PLoS One. 2015;10:e0139001. doi: 10.1371/journal.pone.0139001 26397100
11. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8: 164–72. 17621463
12. Phanuphak N, Ananworanich J, Teeratakulpisarn N, Jadwattanakul T, Kerr SJ, Chomchey N, et al. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Antivir Ther. 2012;17: 1521–31. doi: 10.3851/IMP2497 23220732
13. World Health Organization, WHO Model List of Essential Medicines: 18th list October 2013: http://www.who.int/medicines/publications/essentialmedicines/en/.
14. Ahmed Ouameur A, Marty R, Neault JF, Tajmir-Riahi HA, AZT binds RNA at multiple sites. DNA Cell Biol. 2004;23: 783–8. 15585137
15. Cardenas WB, Evasion of the interferon-mediated antiviral response by filoviruses. Viruses. 2010;2: 262–82. doi: 10.3390/v2010262 21994610
16. Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, Alinger JB, et al. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe. 2014;16: 187–200. doi: 10.1016/j.chom.2014.07.008 25121748
17. Fabozzi G, Nabel CS, Dolan MA, Sullivan NJ, Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J Virol. 2011;85: 2512–23. doi: 10.1128/JVI.01160-10 21228243
18. Chang TH, Kubota T, Matsuoka M, Jones S, Bradfute SB, Bray M, et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 2009;5: e1000493. doi: 10.1371/journal.ppat.1000493 19557165
19. Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, et al. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis. 2013;208: 310–8. doi: 10.1093/infdis/jis921 23255566
20. Qiu X, Wong G, Fernando L, Audet J, Bello A, Strong J, et al. mAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med. 2013;5: 207ra143. doi: 10.1126/scitranslmed.3006605 24132638
21. Qiu X, Wong G, Fernando L, Ennis J, Turner JD, Alimonti JB, et al. Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs. J Virol. 2013;87: 7754–7. doi: 10.1128/JVI.00173-13 23616649
22. Hoenen T, Watt A, Mora A, Feldmann H, Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes. J Vis Exp. 2014;91: 52381. doi: 10.3791/52381 25285674
23. Watt A, Moukambi F, Banadyga L, Groseth A, Callison J, Herwig A, et al. A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity. J Virol. 2014;88: 10511–10524. doi: 10.1128/JVI.01272-14 24965473
24. Hoenen T, Feldmann H, Reverse genetics systems as tools for the development of novel therapies against filoviruses. Expert Rev Anti Infect Ther. 2014;12: 1253–1263. doi: 10.1586/14787210.2014.948848 25169588
25. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013;5:190ra79. doi: 10.1126/scitranslmed.3005471 23785035
26. Chou TC, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58: 621–81. 16968952
27. Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, et al. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Science Transl Med. 2015;7:290ra89.
28. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125: 1714–22. 14724824
29. Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014;14: 1055–64. doi: 10.1016/S1473-3099(14)70937-5 25300863
30. Di Mascio M, Srinivasula S, Bhattacharjee A, Cheng L, Martiniova L, Herscovitch P, et al. Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography. Antimicrob Agents Chemother. 2009;53: 4086–95. doi: 10.1128/AAC.00419-09 19667288
31. Parang K, Wiebe LI, Knaus EE, Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. J Pharm Pharmacol. 1998;50: 989–96. 9811159
32. Ebihara H, Theriault S, Neumann G, Alimonti J, Geisbert J, Hensley L, et al. In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis. 2007;196 Suppl 2:S313–22. 17940966
33. Hoenen T, Jung S, Herwig A, Groseth A, Becker S, Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription. J Virol. 2010;403: 56–66.
34. Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, et al. Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors. J Biol Chem. 2013;288: 23814–22. doi: 10.1074/jbc.M113.476192 23814052